Bioenvision to Present at the 24th Annual JPMorgan Healthcare Conference.

NEW YORK -- Bioenvision, Inc. (Nasdaq: BIVN) announced today that Dr. Christopher B. Wood, Chairman and Chief Executive Officer of the Company, will present at the 24th Annual JPMorgan Healthcare Conference, Tuesday, January 10, 2006, at 11:30 am PST in San Francisco. An audio webcast of the presentation will be available to all interested parties at Bioenvision's website (www.bioenvision.com) or directly accessed by the following link: http://equityconferences.jpmorgan.com.

About clofarabine

Clofarabine is a next generation purine nucleoside analog. This class of drugs inhibits DNA production necessary for cancer cell growth. Bioenvision and Genzyme Corporation (Nasdaq: GENZ) are co-developing clofarabine. Bioenvision holds an exclusive worldwide license for clofarabine (outside Japan and Southeast Asia). Bioenvision granted an exclusive sublicense to Genzyme to develop and commercialize clofarabine for cancer indications in the US and Canada. Bioenvision holds an exclusive license in the US and Canada for all non-cancer indications and an exclusive, irrevocable option to develop and market clofarabine for all human applications in Japan and Southeast Asia.

Bioenvision originally obtained clofarabine development and commercialization rights under patents held by Southern Research Institute.

Clofarabine has been granted orphan drug designation for the treatment of adult and pediatric ALL and AML in the U.S. and Europe. In the U.S., orphan drug status extends market exclusivity for seven years. The FDA also recently granted an additional six months market exclusivity to clofarabine under the Best Pharmaceuticals for Children Act. In Europe, the designation provides marketing exclusivity for 10 years following Market Authorization. In December 2004, FDA approved the use of clofarabine for treatment of pediatric patients 1 to 21 years old with relapsed or refractory ALL after at least two prior regimens.

In Europe, Bioenvision filed a marketing authorization application (MAA) for clofarabine via the Centralized Procedure in July 2004.

About Bioenvision

Bioenvision's primary focus is the acquisition, development, distribution and marketing of compounds and technologies for the treatment of cancer. Bioenvision has a broad pipeline of products for the treatment of cancer, including: clofarabine (in co-development with Genzyme Corporation), Modrenal(R) (for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy), and other products in clinical trials. Bioenvision is also developing anti-infective technologies, including the OLIGON technology; an advanced biomaterial that has been incorporated into various FDA approved medical devices. For more information on Bioenvision please visit our Web site at www.bioenvision.com.

Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and in Bioenvision's compounds under development in particular; the potential failure of Bioenvision's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Bioenvision's compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Bioenvision's business, structure or projections; the development of competing products; uncertainties related to Bioenvision's dependence on third parties and partners; and those risks described in Bioenvision's filings with the SEC. Bioenvision disclaims any obligation to update these forward-looking statements.